Antonio M. Risitano

16.2k total citations · 2 hit papers
200 papers, 8.1k citations indexed

About

Antonio M. Risitano is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Antonio M. Risitano has authored 200 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Immunology, 133 papers in Hematology and 70 papers in Genetics. Recurrent topics in Antonio M. Risitano's work include Complement system in diseases (123 papers), Blood groups and transfusion (56 papers) and Hematopoietic Stem Cell Transplantation (47 papers). Antonio M. Risitano is often cited by papers focused on Complement system in diseases (123 papers), Blood groups and transfusion (56 papers) and Hematopoietic Stem Cell Transplantation (47 papers). Antonio M. Risitano collaborates with scholars based in Italy, United States and United Kingdom. Antonio M. Risitano's co-authors include Jaroslaw P. Maciejewski, Neal S. Young, Hubert Schrezenmeier, John D. Lambris, Peter Hillmen, Robert A. Brodsky, Jeff Szer, Jörg Schubert, Lucio Luzzatto and Régis Peffault de Latour and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nucleic Acids Research.

In The Last Decade

Antonio M. Risitano

189 papers receiving 8.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2006 878 citations Peter Hillmen, Neal S. Young et al. profile →
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2021 249 citations Peter Hillmen, Jeff Szer et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Antonio M. Risitano	5.6k	3.5k	2.5k	1.9k	812	200	8.1k
Russell P. Rother	4.7k 0.8×	2.4k 0.7×	2.0k 0.8×	2.0k 1.0×	989 1.2×	72	7.9k
Paul Coppo	5.6k 1.0×	4.0k 1.1×	2.3k 0.9×	1.8k 0.9×	520 0.6×	248	7.9k
Scott A. Rollins	4.1k 0.7×	1.9k 0.5×	1.4k 0.6×	1.3k 0.7×	1.1k 1.3×	63	7.2k
David Kavanagh	5.8k 1.0×	2.3k 0.7×	3.3k 1.3×	902 0.5×	1.1k 1.4×	138	7.9k
Johanna A. Kremer Hovinga	5.3k 0.9×	3.4k 1.0×	2.6k 1.1×	2.0k 1.0×	429 0.5×	173	7.0k
Yoshihiro Fujimura	4.1k 0.7×	4.4k 1.2×	1.8k 0.7×	1.5k 0.8×	1.3k 1.5×	249	8.1k
Margarita López‐Trascasa	3.5k 0.6×	1.8k 0.5×	1.8k 0.7×	1.3k 0.7×	546 0.7×	126	4.9k
Christoph Licht	3.1k 0.6×	1.3k 0.4×	2.4k 1.0×	561 0.3×	666 0.8×	177	4.9k
Ryotaro Nakamura	2.3k 0.4×	3.0k 0.8×	571 0.2×	1.0k 0.5×	556 0.7×	219	5.6k
X. Long Zheng	3.8k 0.7×	3.2k 0.9×	1.4k 0.6×	1.5k 0.8×	678 0.8×	181	5.9k

Countries citing papers authored by Antonio M. Risitano

Since Specialization

Citations

This map shows the geographic impact of Antonio M. Risitano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio M. Risitano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio M. Risitano more than expected).

Fields of papers citing papers by Antonio M. Risitano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio M. Risitano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio M. Risitano. The network helps show where Antonio M. Risitano may publish in the future.

Co-authorship network of co-authors of Antonio M. Risitano

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio M. Risitano. A scholar is included among the top collaborators of Antonio M. Risitano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio M. Risitano. Antonio M. Risitano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Greco, Raffaella, Annalisa Ruggeri, Donal P. McLornan, et al.. (2025). Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations. Bone Marrow Transplantation. 60(11). 1499–1525.

Cooper, Nichola, David J. Kuter, Henrik Frederiksen, et al.. (2024). Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study. Blood. 144(Supplement 1). 3836–3836. 6 indexed citations

Passweg, Jakob, Helen Baldomero, Fabio Ciceri, et al.. (2024). Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplantation. 59(6). 803–812. 27 indexed citations

Passweg, Jakob, Helen Baldomero, Tobias Alexander, et al.. (2024). Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT. Bone Marrow Transplantation. 60(2). 227–236. 1 indexed citations

Serio, Bianca, Gabriella Storti, Camilla Frieri, et al.. (2024). Post-Transplant Cyclophosphamide versus Anti-Thymocyte Globulin in Patients with Hematological Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Haploidentical and Matched Unrelated Donors: A Real-Life Experience. SHILAP Revista de lepidopterología. 16(2). 234–243.

Risitano, Antonio M., Bing Han, Austin Kulasekararaj, et al.. (2024). Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials. Blood. 144(Supplement 1). 4079–4079. 1 indexed citations

Röth, Alexander, Guangsheng He, Andrés Brodsky, et al.. (2024). Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition. Blood. 144(Supplement 1). 2687–2687.

Risitano, Antonio M., Bing Han, Austin Kulasekararaj, et al.. (2023). Categorization of Hematological Responses to Oral Iptacopan Monotherapy in Anti-C5-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia in the Phase III APPLY-PNH Trial and Complement Inhibitor-Naïve Patients in the Phase III APPOINT-PNH Trial. Blood. 142(Supplement 1). 4084–4084. 4 indexed citations

Risitano, Antonio M., Régis Peffault de Latour, Jun Ho Jang, et al.. (2023). Exposure-Response Relationships between the Complement Factor B Inhibitor Iptacopan and Lactate Dehydrogenase (LDH) and Hemoglobin (Hb) in Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood. 142(Supplement 1). 5643–5643. 1 indexed citations

10.

Risitano, Antonio M., David J. Araten, David J. Kuter, et al.. (2023). PB2063: APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL. HemaSphere. 7(S3). e08587b7–e08587b7. 1 indexed citations

11.

Latour, Régis Peffault de, Jeff Szer, Ilene C. Weitz, et al.. (2022). Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. The Lancet Haematology. 9(9). e648–e659. 43 indexed citations

12.

Risitano, Antonio M., et al.. (2021). Dyskeratosis congenita and squamous cell carcinoma of the mandibular alveolar ridge. BMJ Case Reports. 14(5). e242459–e242459. 5 indexed citations

13.

Nagler, Arnon, Myriam Labopin, Bhagirathbhai Dholaria, et al.. (2020). Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. Clinical Cancer Research. 27(3). 843–851. 26 indexed citations

14.

Dufour, Carlo, et al.. (2020). Hepatitis-Associated Aplastic Anemia. Hematology/Oncology and Stem Cell Therapy. 15(2). 8–12. 17 indexed citations

15.

Castro, Carlos de, Peter Hillmen, Jeff Szer, et al.. (2020). CT-286: Results of the PEGASUS Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. Clinical Lymphoma Myeloma & Leukemia. 20. S216–S217. 1 indexed citations

16.

Mastellos, Dimitrios C., Despina Yancopoulou, Petros Kokkinos, et al.. (2015). Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation. 45(4). 423–440. 170 indexed citations

17.

Maury, Sébastien, Simona Pollichieni, Rosi Oneto, et al.. (2013). Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia. American Journal of Hematology. 88(10). 868–873. 9 indexed citations

18.

Risitano, Antonio M. & Fabiana Perna. (2011). Aplastic Anemia: Immunosuppressive Therapy in 2010. SHILAP Revista de lepidopterología. 3(12). e7–e7. 3 indexed citations

19.

Brodsky, Robert A., Neal S. Young, Elisabetta Antonioli, et al.. (2007). Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 111(4). 1840–1847. 457 indexed citations

20.

O’Keefe, Christine L., Magdalena Plašilová, Marcin W. Włodarski, et al.. (2004). Molecular Analysis of TCR Clonotypes in LGL: A Clonal Model for Polyclonal Responses. The Journal of Immunology. 172(3). 1960–1969. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact